References
- Rand KD, Andersen MD, Olsen OH, et al. The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry. J Biol Chem 2008;283(19):13378-87
- Tranholm M, Kristensen K, Kristensen AT, et al. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003;102(10):3615-20
- Persson E, Olsen OH, Bjorn SE, Ezban M. Vatreptacog alfa from conception to clinical proof of concept. Semin Thromb Hemost 2012;38(3):274-81
- de Paula EV, Kavakli K, Mahlangu J, et al. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost 2012;10(1):81-9
- Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet 2009;24(4):318-32
- Baker K, Qiao SW, Kuo T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol 2009;31(2):223-36
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7(9):715-25
- Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013;369(24):2313-23
- Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014;123(3):317-25
- Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res 2013;131(Suppl 2):S2-6
- Maroney SA, Ellery PE, Wood JP, et al. Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)alpha and TFPIbeta. J Thromb Haemost 2013;11(5):911-18
- Maroney SA, Cooley BC, Ferrel JP, et al. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci USA 2012;109(10):3927-31
- Wood JP, Bunce MW, Maroney SA, et al. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci USA 2013;110(44):17838-43